Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00801437
First received: November 19, 2008
Last updated: June 28, 2011
Last verified: June 2011

November 19, 2008
June 28, 2011
October 2008
June 2009   (final data collection date for primary outcome measure)
  • Incidence of ocular hyperemia [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • safety of treatment [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00801437 on ClinicalTrials.gov Archive Site
effectiveness in IOP lowering [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance.

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients >18 years with primary open angle glaucoma or ocular hypertension

Glaucoma, Open-angle
Drug: Xalacom
Xalacom 1 drop into the affected eye daily
Xalacom treatment
patients with primary glaucoma
Intervention: Drug: Xalacom
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
457
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • primary open angle glaucoma
  • ocular hypertension
  • age >18 years

Exclusion Criteria:

  • bradycardia
  • obstructive pulmonary disease
  • hypersensitivity to the drug
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Slovakia
 
NCT00801437
A6641053
No
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP